When the bosses of some of the world's largest pharmaceutical companies headed to Washington in January to meet U.S. President Donald Trump, it had all the makings of a potentially hostile meeting.
Pharmaceutical stocks leapt on Wednesday as Republican Donald Trump's U.S. presidential election win led investors to conclude the threat of tough action on drug pricing had receded. News that a Californian proposal aimed at reining in rising prices for prescription drugs was headed for defeat in a state ballot also buoyed the mood.

Valeant Pharmaceuticals International Inc will likely offer cash an

Merck KGaA agreed to buy Sigma- Aldrich Corp. for $17 billion in cash to expand in chemicals used in research labs and pharmaceutical manufacturing and reduce its dependence on drug development.
Pharmaceutical companies, such as Pfizer, are scrambling to develop new products as patents are approaching expiration